Elite Pharmaceuticals, Inc. to Present Clinical Data at the American Academy of Pain Medicine's 24th Annual Meeting
February 14 2008 - 8:00AM
Business Wire
Elite Pharmaceuticals, Inc. (AMEX: ELI), a leading drug delivery,
specialty pharmaceutical company focused primarily on developing
and commercializing proprietary abuse resistant, extended release
pain compounds, today announced that the Company will be presenting
clinical data on the dose-response reduction of opioid-induced
euphoria from naltrexone, at the American Academy of Pain
Medicine�s (AAPM) 24th Annual Meeting taking place at the Gaylord
Palms Resort in Orlando, FL on February 14-16. Dr. Stuart Apfel,
Elite�s Chief Medical Officer, commented, �We are honored to have
been selected to present our findings at this year�s AAPM. This
study illustrates the fact that varying ratios of the opioid and
naltrexone, in a combination formulation, may�impact differently on
a subject�s euphoria and related sensations. We are not aware of
any previous published studies that demonstrate this observation.
The study suggests that the ratio of agonist to antagonist is an
important consideration in combination drugs designed to deter
tampering or abuse of opioid analgesics.� Lynn Webster, M.D., head
of Lifetree Clinical Research in Salt Lake City, and the lead
investigator for the abuse-deterrent study, said, "Prescription
drug abuse is a national crisis. If we are going to use powerful
pain killers like opioids we need them to be less attractive to
abuse. Elite is advancing a formulation which may help deter abuse
while providing a medication that will be effective in treating
intractable pain." About the American Academy of Pain Medicine�s
(AAPM�s) 24th Annual Meeting AAPM has evolved as the primary
organization for physicians practicing the specialty of pain
medicine in the United States. As the practice of pain medicine has
grown, a defined body of knowledge and scope of practice have
emerged, and today pain medicine is recognized as a discrete
specialty by the American Medical Association (AMA). AAPM is the
only pain medicine organization with representation in the AMA. The
meeting expects to draw more than 800 attendees from across the
country practicing in various areas of medicine including:
anesthesiology, physical medicine and rehabilitation, neurology,
internal medicine, neurosurgery, psychiatry, family practice among
others. The educational programming will offer the most current
information about the diagnosis, treatment, and management of acute
pain, chronic cancer and non-cancer pain, and recurrent pain. About
Lifetree Clinical Research Lifetree Clinical Research� is a
privately-held company, headquartered in Salt Lake City, Utah.
Lifetree�s clinicians are recognized clinical and regulatory
thought leaders in protocol design, implementation and oversight.
Lifetree is dedicated to supporting the pharmaceutical, device, and
biotechnology industries by providing unparalleled service and
becoming an indispensable drug development partner. For more
detailed information about Lifetree Clinical Research�, please
visit www.lifetreeresearch.com. About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals www.elitepharma.com is a specialty
pharmaceutical company principally engaged in the development and
manufacturing of oral controlled-release products. The Company's
strategy includes developing generic versions of controlled release
drug products with high barriers to entry and assisting partner
companies in the life cycle management of products to improve
off-patent drug products. Elite's technology is applicable to
develop delayed, sustained or targeted release capsules or tablets.
Elite has two products currently being sold commercially and a
pipeline of seven drug products under development in the
therapeutic areas that include pain management, allergy and
infection. The addressable market for Elite's current pipeline of
products exceeds $6 billion. Elite formed, together with VGS
Pharma, LLC, Novel Laboratories, Inc., as a separate specialty
pharmaceutical company for the research, development,
manufacturing, licensing and acquisition of specialty generic
pharmaceuticals. Elite operates a GMP and DEA registered facility
for research, development, and manufacturing located in Northvale,
NJ. This news release contains forward-looking statements,
including those related to the preliminary nature of the clinical
program results and the potential for further product development,
that involve known and unknown risks, delays, uncertainties and
other factors not under the control of the Company, which may cause
actual results, performance or achievements of the companies to be
materially different from the results, performance or other
expectations implied by these forward-looking statements. In
particular, because substantial future testing will be required
prior to approval, the results described above may not be supported
by additional data or by the results of subsequent trials. These
risks and other factors, including the timing or results of pending
and future clinical trials, regulatory reviews and approvals by the
Food and Drug Administration and other regulatory authorities, and
intellectual property protections and defenses, are discussed in
Elite's filings with the Securities and Exchange Commission such as
the 10K, 10Q and 8K reports. The Company undertakes no obligation
to update any forward-looking statements.
Elite Pharmaceuticals (AMEX:ELI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Elite Pharmaceuticals (AMEX:ELI)
Historical Stock Chart
From Oct 2023 to Oct 2024